NASDAQ:ALRN Aileron Therapeutics (ALRN) Stock Price, News & Analysis $3.61 -0.09 (-2.43%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Aileron Therapeutics Stock (NASDAQ:ALRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aileron Therapeutics alerts:Sign Up Key Stats Today's Range$3.56▼$3.7050-Day Range$1.65▼$3.7352-Week Range$1.01▼$7.42Volume34,098 shsAverage Volume71,433 shsMarket Capitalization$78.03 millionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingStrong Buy Company OverviewAileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.Read More… Crypto’s next big bull run? (Ad)Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …And one special coin could do even better. Aileron Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks60th Percentile Overall ScoreALRN MarketRank™: Aileron Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 497th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingAileron Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAileron Therapeutics has received no research coverage in the past 90 days.Read more about Aileron Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aileron Therapeutics are expected to grow in the coming year, from ($1.41) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aileron Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aileron Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAileron Therapeutics has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aileron Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.52% of the float of Aileron Therapeutics has been sold short.Short Interest Ratio / Days to CoverAileron Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Aileron Therapeutics has recently increased by 15.83%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAileron Therapeutics does not currently pay a dividend.Dividend GrowthAileron Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.52% of the float of Aileron Therapeutics has been sold short.Short Interest Ratio / Days to CoverAileron Therapeutics has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Aileron Therapeutics has recently increased by 15.83%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.76 News SentimentAileron Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aileron Therapeutics this week, compared to 1 article on an average week.Search Interest1 people have searched for ALRN on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Aileron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.57% of the stock of Aileron Therapeutics is held by insiders.Percentage Held by Institutions90.89% of the stock of Aileron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aileron Therapeutics' insider trading history. Receive ALRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALRN Stock News HeadlinesAileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Increase in Short InterestOctober 16 at 4:59 AM | americanbankingnews.comAileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway FibrosisOctober 12, 2024 | prnewswire.comCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …October 17, 2024 | Weiss Ratings (Ad)Aileron Therapeutics (NASDAQ:ALRN) Stock, Insider Trading ActivityOctober 6, 2024 | benzinga.comAileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)September 23, 2024 | prnewswire.comAileron Therapeutics reports voting results from annual meetingAugust 24, 2024 | investing.comAileron Therapeutics to Present at the 8th Annual IPF SummitAugust 19, 2024 | prnewswire.comAileron Therapeutics, Inc.: Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business HighlightsAugust 15, 2024 | finanznachrichten.deSee More Headlines ALRN Stock Analysis - Frequently Asked Questions How have ALRN shares performed this year? Aileron Therapeutics' stock was trading at $3.05 on January 1st, 2024. Since then, ALRN shares have increased by 18.4% and is now trading at $3.61. View the best growth stocks for 2024 here. How were Aileron Therapeutics' earnings last quarter? Aileron Therapeutics, Inc. (NASDAQ:ALRN) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by $0.20. When did Aileron Therapeutics' stock split? Aileron Therapeutics's stock reverse split before market open on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Aileron Therapeutics IPO? Aileron Therapeutics (ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers. How do I buy shares of Aileron Therapeutics? Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Aileron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aileron Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN). Company Calendar Last Earnings8/14/2024Today10/17/2024Next Earnings (Estimated)10/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALRN CUSIPN/A CIK1420565 Webwww.aileronrx.com Phone(617) 995-0900FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+426.3%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,730,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.88% Return on Assets-30.81% Debt Debt-to-Equity RatioN/A Current Ratio4.69 Quick Ratio4.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book2.56Miscellaneous Outstanding Shares21,615,000Free Float20,561,000Market Cap$78.03 million OptionableNot Optionable Beta2.35 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ALRN) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aileron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aileron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.